Dear colleague,The past couple of months have been filled with valuable exchanges with our Takeda teams all around the globe. Our Takeda-ism guiding us along the way. In this second newsletter, we would like to share with you the latest Market Research Findings from China, US and India. | |
|---|
|
|---|
On the road
with the Albu-Team | |
|---|
|
|---|
| China Market
Research  |
|---|
|
|---|
Completed: | 122 Interviews with Hospital presidents, hepatologists, oncologists, IDs, head nurses, hospital pharmacists, retail pharmacists, competitors, and distributors (in partnership with IPSOS and IQVIA) |
|---|
|
|---|
| 280 Surveys with Retail and Hospital Pharmacists (IQVIA) |
|---|
|
|---|
| 55,000 Online Datapoints (IPSOS) |
|---|
|
|---|
|
|---|
|
|---|
In Progress: | 1,200 Surveys to follow up on Qual findings (IPSOS) |
|---|
|
|---|
| 720 Surveys to determine forecasting variables (IQVIA) |
|---|
|
|---|
| 10 Interviews to follow up on specific CI questions- CSL, Grifols, Hualan, SH/GZ/BJ (IQVIA) |
|---|
|
|---|
|
|---|
|
|---|
Key Findings: | Tier 3 & Tier 4 cities are growing faster than Tier 1 & Tier 2 cities. |
|---|
|
|---|
| Tier 3 & Tier 4 + cities have an albumin market size of $1.7bn and are already almost 3x larger than the US ($600m). |
|---|
|
|---|
| The strongest differentiator for our Flexbumin® product is the closed system administration which reduces the probability of central line associated blood stream infections (CLABSIs). |
|---|
|
|---|
|
|---|
|
|---|
| USA Market
Research |
|---|
|
|---|
Completed: | 28 Interviews and 13 In-Facility Focus Groups (21 participants) in Chicago and Boston through web-assisted telephone interviews (WATIs) with Directors of Pharmacy, Urgent Care Dept. Heads, Qual/Safe directors, Infectious Disease Specialists, Pharm. Tech/Pharmacists, Nurses/Nurse Managers (In partnership with Throughline Strategy) |
|---|
|
|---|
|
|---|
|
|---|
Key Findings: | Albumin is viewed positively as an essential therapy to support patients' health. |
|---|
|
|---|
| Brand awareness is extremely low. |
|---|
|
|---|
| Price, product availability and packaging are key differentiators. |
|---|
|
|---|
| Healthcare Professionals (HCPs) identified the number one benefit of Flexbumin® to be its closed system as it could protect patients by reducing (CLABSIs). |
|---|
|
|---|
|
|---|
|
|---|
| India Market
Research |
|---|
|
|---|
Completed: | 4 groups of physicians and 3 groups of purchasers qualitative explorative 90 minute interviews (sample of 4 respondents, on average, per group - in partnership with reasearch partnership) |
|---|
|
|---|
|
|---|
|
|---|
Key Findings: | Hospital Acquired Infections(HAIs) are feared, costly and can be seen as an "injustice" to patients. They extend hospital stay and attendants have to bear the cost (2-10 lakhs or 2,000-12,000€). |
|---|
|
|---|
| Ensuring patient safety and HAI prevention is considered to be extremely important. |
|---|
|
|---|
| HCPs indetified the number one benefit of Flexbumin® to be the closed system as it could protect patients by reducing CLABSIs as well as reduce the associated economic burden. |
|---|
|
|---|
| The shatterproof benefit also ranked high as an added value. |
|---|
|
|---|
|
|---|
|
|---|
Global War GameTwo-day workshop in Boston, MA, USA | |
|---|
|
|---|
| PORTFOLIO: Flexbumin®, Glass Albumin, Flexumin®2.0 |
|---|
|
|---|
| MAJOR COMPETITORS: Grifols, CSL Behring |
|---|
|
|---|
| KEY EVENTS: AMBAR trial, Albutein Flexbag Launch |
|---|
|
|---|
|
|---|
|
|---|
Milestones  | |
|---|
|
|---|
For any suggestions,
questions or feedback,
please reach out to: Frederic Chapuis
Global Commercial Lead
Rare Specialty Care
(Albumin/Coagulation)
Immunology Franchise
frederic.chapuis@takeda.com
 Christian Hoffmann
Insights lead - Immunology
(BioT, Transplan, New Products)
Patient Value & Product Strategy
(PVPS)
carlchristian.hoffmann@takeda.com
We would love to hear from you!Stay tuned for more updates soon!Yours,The Albu-Team | |
|---|
|
|---|
 |
|
